Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_31a6101ff58fccadb5eacefd25fd1556 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5e5c121269689cbab9b3a4548b15caf3 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-73 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-94 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-13 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-56 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-46 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K1-306 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-1018 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2842 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-286 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4703 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-46 |
filingDate |
2017-11-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c47da58e777772bdeb8733b950b6b387 |
publicationDate |
2019-09-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
EP-3539992-A1 |
titleOfInvention |
Fragment antibody and method for crystallizing protein using fragment antibody |
abstract |
An object of the present invention is to provide a fragment antibody which can be conveniently produced as one having antigen-binding activity, and which has a greater ability to crystallize itself alone or as a complex with an antigen molecule than that of Fv-clasp (v1) even in a case where the fragment antibody is obtained in anexpression system. The present invention relates to a fragment antibody including a complex of a peptide (VH(112C)-SARAH) in which an N-terminus of a SARAH domain is linked to a C-terminus of a heavy chain domain (VH region) of an antibody, and an amino acid residue of antibody residue 112 according to Chothia numbering scheme in the VH region is mutated to cysteine; and a peptide (VL-SARAH(37C)) in which an N-terminus of a SARAH domain is linked to a C-terminus of a light chain domain (VL region) of an antibody, and an amino acid residue at position 13 from the C-terminus in the SARAH domain is mutated to cysteine. |
priorityDate |
2016-11-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |